3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Head and Neck Squamous Cell Cancer
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
28
Nivolumab
13
Carboplatin
9
fludarabine
7
Paclitaxel
7
Gemcitabine
7
Docetaxel
7
Cyclophosphamide
7
Cisplatin
7
Trastuzumab
5
palbociclib
4
cemiplimab
4
avelumab
4
atezolizumab
4
Ipilimumab
4
Fluorouracil
4
Filgrastim
4
Drug Therapy
4
Cetuximab
4
fludarabine phosphate
3
epacadostat
3
durvalumab
3
Taxes
3
Oxaliplatin
3
Fulvestrant
3
zimberelimab
2
ulixertinib
2
trametinib
2
tisotumab vedotin
2
spartalizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
rocakinogene sifuplasmid
×
Head & Neck
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled